Skip to main content
Sign In
 

Fred Hirsch, M.D., PhD- Publications & Abstracts


2012

Publications

Christoph DC, Mascaux C, Reyna Asuncion B, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WEE, Hirsch FR.
Folylpoly-Glutamate Synthetase Expression is associated with Tumor Response and Outcame from Pemetrexed -based Chemotherapy in Malignant Pleural Mesothelioma.
Submitted J Thorac. Oncol

Ekman S., Wynes MW, Hirsch FR.
The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis. 
Under revision in J Thorac Oncol

Christoph DC, Hoffmann AC, Gauler TC, Reyna Asuncion B, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhardt WEE, Hirsch FR
Detection of circulating lung cancer cells with strong TS-reasctivity in the peripheral blood of patient with pulmonary adenocarcinoma treated with pemetrexed.
J Thorac Oncol. 2012 Apr;7(4):766-7

Wynes MW, Konopa K, Singh S, Asuncion BR, Ranger-Moore J, Sternau A, Christoph DC, Dzidziuszko R, Jassem J, Hirsch FR
Thymidylate Synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
J Thorac Oncol.

Samir E. Witta, Robert M. Jotte, Katrik Konduri, Marcus A. Neubauer, Alexander I. Spira, Robert L. Ruxer,
Marileila Varella-Garcia, Paul A. Bunn Jr, and Fred R. Hirsch
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
J Clin Oncol. 2012 Apr 16. PMID:22425929

Weickhardt AJ, Doebele R, Oton AB, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson M, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR.
A phase I/II study of erlotinib in combination with the anti-Insulin-Like Growth Factor-1 Receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
J Thorac Oncol. 2012 Jan 10. [Epub ahead of print]. PMID:22237261

Dzidziuszko R, Wynes MW, Singh S, Asuncion BR, Rnager-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR
Correlation between MET gene copy number by Silver In-Situ Hybridization and Protein Expression by Immunochistochemistry in non-small cell lung cancer.
J Thorac Oncol. 2012 jan 10. [Epub ahead of print] PMID:22237262

2011

Publications

Salido M,, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer 

J Thorac Oncol. 2011 Jan;6(1):21-7.PMID:21107285

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Jr. Camidge R.
A randomized phase II biomarker selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small cell lung cancer.
J Clin Oncol  29( 26): 3567-73. 2011. PMID:21825259

Arriola E. Canadas I, Arumi-Uria M, Domine M, Lopez-Vilarino JA, Arpi O, Salido M, Menendez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J.
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition has antitumor activity in MET mutant cell lines.
Br J Cancer, 105 (6): 814-23. 2011. PMID:21847116

Barash O, Peled N, Tisch U, Bunn, Jr., PA, Hirsch FR, Haick H.
Classification of the lung cancer histology by gold nanoparticle sensors.
Nanomedicine. 2011 Oct 25 PMID:22033081

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rossell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society/International Multidisciplinary classification of lung adenocarcinoma.
J Thorac Oncol 6: 244-285, 2011.

Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA.
Fiding ALK-positive lung cancer: what are we really looking for?
J Thorac Oncol 6: 411-413, 2011 PMID:21317739

Mascaux C. Wynes M.W., Yasufumi K., Tran C., Reyna Asuncion B. Zhao J., Gustavson M., Ranger-Moore J., Gaire F.,  Matsubayashi J., Nagao T., Yoshida K., Ohira T., Ikeda N., Hirsch F.R.
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor - A novel antibody for immunohistochemistry or AQUA technology.
Clin Cancer Res. 2011 Dec 15;17(24):7796-807. PMID:21994417

Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA, Jr., Geraci MW, Miller YE.
Oral Iloprost improves endobronchial dysplasia in former smokers.
Cancer Prev Res (Phila). 2011 Jun;4(6):793-802.PMID:21636546

Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F.
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
Clin Cancer Res. 2011 Aug 15;17(16):5257-67.PMID:21712447

Abstracts

Merrick D.T., Coldren C.D., Franklin W, Sugita M, Miller Y.E., Keith R.L., Kennedy T.C., Chesnut P., Mascaux C., Hirsch F.R., Geraci M.W., Nemenoff R.
Identification of Alterations in Gene Expression that Distinguish Persistent from Regressive Bronchial Dysplasia.
14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 2011, WCLC proceeding 2011, P2.252.

 

Christoph D.C., Mascaux C., Wynes M.W., Reyna Asuncion B., Wohlschlaeger J., Theegarten D., Gauler T.C., Schuler M.H., Eberhardt W.E.E., Hirsch F.R.
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma.
14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 2011, WCLC proceeding 2011, P2.247.

Wynes M.W., Kato Y., Mascaux C., Reyna Asuncion B.G., Sanchez S.A., Matsubayashi J., Yoshida K., Nagao T., Furukawa K., Ikeda N., Hirsch F.R.
Immunohistochemistry using an EGFR internal domain-specific antibody predicts response and outcome to an EGFR tyrosine kinase inhibitor.

14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 2011, WCLC proceeding 2011, MO10.10

Kato Y., Wynes M.W., Mascaux C., Reyna Asuncion B., Tran C., Yoshida K., Matsubayashi J., Nakajima E., Ohira T., Nagao T., Furukawa K., Ikeda N. Hirsch F.R.
IGF-1R as a predictive marker for EGFR TKI (Gefitinib) resistance in Non Small Cell Lung Cancer using IHC and AQUA technology.
14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 2011, WCLC proceeding 2011, O
39.03

Christoph D.C., Mascaux C., Wynes M.W., Reyna Asuncion B., Wohlschlaeger J., Theegarten D., Gauler T.C., Schuler M.H., Eberhardt W.E.E., Hirsch F.R.

Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma.
2011 ASCO Annual Meeting, Chicago, IL, USA, June 2011. J Clin Oncol 2011, 29, suppl, abstract 7024
Kato Y., Mascaux C., Wynes M.W., Reyna Asuncion B., Tran C., Yoshida K., Matsubayashi J., Nakajima E., Ohira T., Nagao T., Furukawa K., Ikeda N. Hirsch F.R.
The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology.
2011 ASCO Annual Meeting, Chicago, IL, USA, June 2011. J Clin Oncol 2011, 29, suppl, abstract 10556

 

 

2010

Publications

Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR.
Early detection and screening of lung cancer.
Expert Rev Mol Diagn. 2010 Sep;10(6):799-815. PMID:20843203

Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr.
The tissue is the issue: personalized medicine for non-small cell lung cancer.
Clin Cancer Res. 2010 Oct 15;16(20):4909-11. PMID:20926402

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R;
European EGFR Workshop Group.  Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
J Thorac Oncol. 2010 Oct;5(10):1706-13. PMID:20871269

Patz EF Jr, Caporaso NE, Dubinett SM, Massion PP, Hirsch FR, Minna JD, Gatsonis C, Duan F, Adams A, Apgar C, Medina RM, Aberle DR.
National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.
J Thorac Oncol. 2010 Oct;5(10):1502-6. PMID:20871260

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR.
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
J Thorac Oncol. 2010 Oct;5(10):1551-8.PMID:20697298

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
J Clin Oncol. 2010 Nov 1;28(31):4747-54. PMID:20921467

Hirsch FR.
November--lung cancer awareness month!
J Thorac Oncol. 2010 Nov;5(11):1719-20. PMID:20975370 

Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA Jr, Varella-Garcia M, Hirsch FR.
Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
J Clin Oncol. 2010 May 1;28(13):2174-80. PMID:20351332

Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. 
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Clin Cancer Res. 2010 Jun 15;16(12):3193-204. PMID:20530704

Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, Kowalczyk A, Singh S, Ranger-Moore J, Manriquez G, Gaire F, Jassem J, Hirsch FR.
Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. 
J Thorac Oncol. 2010 Dec;5(12):1905-11. PMID:21124078

Bunn PA Jr, Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, Franklin W. 
Biomarkers are here to stay for clinical research and standard care. 
J Thorac Oncol. 2010 Aug;5(8):1113-5. PMID:20661083

Hirsch FR, Mok TS, Borges V, Bunn PA Jr.
Molecularly targeted therapy: when to stop and when to continue?
Lancet Oncol. 2010 Aug;11(8):709-11. PMID:20570560

Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA. 
The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. 
Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. PMID:20332298 

Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y. 
Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. 
J Thorac Oncol. 2010 Apr;5(4):411-4. PMID:20357614

Abstracts

Wynes M.W., Mascaux C., Kato Y., Reyna-Asuncion B., Zhao J., Powell W., Ranger-Moore J., Yoshida K., Ikeda N., Hirsch F.R.
Prediction of tesponse to Gefitinib in NSCLC by EGFR protein expression is increased by a novel antibody and the use of AQUA technology.
Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, USA, December 2010, S504, abstract 10

Kato Y., Peled N., Yoshida K., Wynes M. W., Pardo M., Mascaux C., Tsuboi M., Ohira T., Ikeda N., Hirsch F.R.
Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies.,
2010 ASCO Annual Meeting, Chicago, IL, USA, June 2010, ASCO meeting proceedings 2010, page733s abstract 10542

 

 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.